Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Ophthalmology

The Long Road: Prognosis and Lifelong Monitoring

At a Glance

Neovascular glaucoma requires lifelong monitoring, with about 50% of patients achieving stable vision. Protecting your vision depends on early treatment, regular eye pressure checks, and strict management of underlying health conditions like diabetes and high blood pressure.

Managing neovascular glaucoma (NVG) is a marathon, not a sprint. Because this condition is tied to the health of your entire vascular system, it requires lifelong vigilance and a commitment to frequent medical checkups [1][2]. While the road ahead can be difficult, being honest about the challenges allows you to plan effectively for your future and your health.

Understanding the Prognosis

NVG is a severe condition, and even with the best modern treatments, the visual prognosis can be guarded [3].

  • The 50/50 Reality: Statistics show that approximately 50% of eyes with NVG achieve stable visual outcomes [4][5]. The outcome often depends on how much damage occurred before treatment began [6][7].
  • Early Intervention: Patients who are treated before the drainage angle “zips” shut (before the angle-closure stage) typically have a better chance of preserving vision [6][8].
  • Systemic Health: Because NVG is often a sign of advanced systemic disease (like diabetes or high blood pressure), your overall health greatly impacts the long-term survival of your vision [9][10].

The Routine: What Long-Term Monitoring Looks Like

Even when your eye pressure is stable and the abnormal vessels have regressed, the “SOS” signal (VEGF) can return if the underlying oxygen shortage isn’t managed [11][12].

  • Frequency of Visits: Initially, you may see your specialists weekly or monthly. As the eye stabilizes, this may move to every three to six months [1][13].
  • Key Tests: At every visit, your doctor will likely perform gonioscopy—using a special lens to check the drainage angle for new vessel growth or scarring [14][15]. They will also carefully check your IOP (intraocular pressure) and the back of your eye [1].

Preventing “The Other Eye” from Developing NVG

If the cause of your NVG is a systemic condition like diabetes or high blood pressure, your other eye is also at risk [16][10].

  • Control the “Big Three”: Managing your HbA1c (blood sugar), blood pressure, and cholesterol is the single best way to prevent the second eye from suffering the same fate [17][18][7].
  • Proactive Screening: Your doctor will likely monitor your “good eye” for signs of retinal ischemia (oxygen starvation) before any new vessels even appear [19][20].

The Psychological Toll

Living with a chronic, sight-threatening condition like NVG is emotionally exhausting. It is normal to experience:

  • “Scanxiety”: Anxiety leading up to eye exams or pressure checks.
  • Grief: Feeling a sense of loss for the vision you had before the diagnosis.
  • Fear: Worrying about the future of your independence or the health of your other eye.

Do not hesitate to seek support from a mental health professional or a support group for people with low vision. Your emotional resilience is just as important as your medical treatment in navigating life with NVG [21][9].

Warning Signs of Recurrence: Urgent Action Needed

If you have already been treated for NVG, contact your specialist immediately if you notice:

  1. A new, deep aching pain in or around the eye.
  2. Halos or rainbow-colored rings around lights.
  3. Sudden cloudiness or a “foggy” quality to your vision.
  4. Increased redness in the eye that doesn’t go away.

Urgent Action: If you experience these symptoms, go to an eye emergency room or call your retina or glaucoma specialist’s after-hours line immediately—do not wait for your regularly scheduled appointment.

Common questions in this guide

What is the visual prognosis for neovascular glaucoma?
While NVG is a severe condition, about 50% of eyes achieve stable visual outcomes with modern treatment. The prognosis depends heavily on how much damage occurred before treatment began and your overall systemic health.
How often will I need follow-up eye exams for NVG?
Initially, you may need to see your specialist weekly or monthly to closely monitor your eye pressure. As your condition stabilizes, these routine visits may be spaced out to every three to six months.
How can I prevent neovascular glaucoma from developing in my other eye?
The best way to protect your healthy eye is by controlling systemic risk factors like blood sugar, blood pressure, and cholesterol. Your eye doctor will also proactively screen your good eye for signs of oxygen starvation.
What are the warning signs that my neovascular glaucoma is returning?
Urgent warning signs include a deep aching pain around the eye, seeing halos around lights, sudden cloudy vision, or persistent eye redness. If you experience these symptoms, you should seek emergency eye care immediately.
What happens during a routine NVG monitoring appointment?
Your doctor will check your intraocular pressure and examine the back of your eye. They will also perform gonioscopy, which uses a special lens to check the eye's drainage angle for new abnormal blood vessel growth or scarring.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the current damage to my eye, what is a realistic expectation for my vision one year from now?
  2. 2.How often will I need to return for follow-up exams (weekly, monthly, quarterly) now that my condition is stable?
  3. 3.What specific 'red flag' symptoms should I watch for in my other eye?
  4. 4.Is my other eye showing any signs of oxygen deprivation (ischemia) that we should treat preventatively?
  5. 5.Can you recommend a therapist or support group that works with patients facing chronic vision loss?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Neovascular Glaucoma from Ocular Ischemic Syndrome Treated with Serial Monthly Intravitreal Bevacizumab and Panretinal Photocoagulation: A Case Report.

    Asif H, Si Z, Quan S, et al.

    Case reports in ophthalmological medicine 2022; (2022()):4959522 doi:10.1155/2022/4959522.

    PMID: 35935916
  2. 2

    Neovascular Glaucoma: An Update.

    Kalogeropoulos D, Moussa G, Sung VC, et al.

    Klinische Monatsblatter fur Augenheilkunde 2023; (240(3)):305-315 doi:10.1055/a-1956-9348.

    PMID: 36436509
  3. 3

    Management of Neovascular Glaucoma.

    Lidder AK, Paranjpe V, Lauter AJ

    International ophthalmology clinics 2023; (63(4)):167-183 doi:10.1097/IIO.0000000000000480.

    PMID: 37755450
  4. 4

    Outcomes of neovascular glaucoma in eyes presenting with moderate to good visual potential.

    Rani PK, Sen P, Sahoo NK, et al.

    International ophthalmology 2021; (41(7)):2359-2368 doi:10.1007/s10792-021-01789-y.

    PMID: 33745037
  5. 5

    Neovascular Glaucoma: A Retrospective Review from a Tertiary Eye Care Center in Mexico.

    Lazcano-Gomez G, R Soohoo J, Lynch A, et al.

    Journal of current glaucoma practice 2017; (11(2)):48-51 doi:10.5005/jp-journals-10028-1222.

    PMID: 28924338
  6. 6

    Surgical outcomes including visual improvement after glaucoma surgery in patients with neovascular glaucoma.

    Chey JH, Lee CK

    Heliyon 2024; (10(7)):e28938 doi:10.1016/j.heliyon.2024.e28938.

    PMID: 38623239
  7. 7

    Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion.

    Rong AJ, Swaminathan SS, Vanner EA, Parrish RK

    American journal of ophthalmology 2019; (204()):62-69 doi:10.1016/j.ajo.2019.02.038.

    PMID: 30862502
  8. 8

    Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion.

    Rong AJ, Swaminathan SS, Vanner EA, Parrish RK

    American journal of ophthalmology 2019; (205()):201-202 doi:10.1016/j.ajo.2019.04.029.

    PMID: 31277883
  9. 9

    Survival in Patients with Neovascular Glaucoma Following Tube Shunt Implant or Cyclodestructive Procedure.

    Zhou Y, Coleman S, Boysen J, et al.

    Journal of current glaucoma practice 2022; (16(2)):74-78 doi:10.5005/jp-journals-10078-1357.

    PMID: 36128084
  10. 10

    Mortality in neovascular glaucoma.

    Taylor KC, Shiromani S, Smolar ALO, et al.

    Indian journal of ophthalmology 2026; (74(1)):81-86 doi:10.4103/IJO.IJO_1421_25.

    PMID: 41460135
  11. 11

    Aqueous Inflammation and Ischemia-Related Biomarkers in Neovascular Glaucoma with Stable Iris Neovascularization.

    Sun C, Zhang H, Tang Y, et al.

    Current eye research 2020; (45(12)):1504-1513 doi:10.1080/02713683.2020.1762226.

    PMID: 32339463
  12. 12

    Neovascular glaucoma - A review.

    Senthil S, Dada T, Das T, et al.

    Indian journal of ophthalmology 2021; (69(3)):525-534 doi:10.4103/ijo.IJO_1591_20.

    PMID: 33595466
  13. 13

    The role of Anti-VEGF agents in treatment of neovascular glaucoma.

    Palfi Salavat MC, Șeclăman EP, Barac R, et al.

    Romanian journal of ophthalmology 2022; (66(3)):209-213 doi:10.22336/rjo.2022.41.

    PMID: 36349171
  14. 14

    Neovascular glaucoma incidence and visual outcomes in treated proliferative diabetic retinopathy with anterior segment neovascularisation.

    Fiddimore E, Al-Janabi A, Sulur Sundararajan R, Gallagher K

    Eye (London, England) 2026; (40(1)):77-82 doi:10.1038/s41433-025-04099-0.

    PMID: 41188570
  15. 15

    Angle-closure assessment in anterior segment OCT images via deep learning.

    Hao H, Zhao Y, Yan Q, et al.

    Medical image analysis 2021; (69()):101956 doi:10.1016/j.media.2021.101956.

    PMID: 33550010
  16. 16

    Long-Term Risk of Mortality and Systemic Morbidity in Neovascular Glaucoma: A Multicenter Retrospective Cohort Study.

    Margolis R, Vasu P, Dorairaj SK

    Ophthalmology. Glaucoma 2026; doi:10.1016/j.ogla.2026.01.017.

    PMID: 41654189
  17. 17

    Frequency and Risk Factors for Neovascular Glaucoma After Vitrectomy in Eyes with Diabetic Retinopathy: An Observational Study.

    Liang X, Zhang Y, Li YP, et al.

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2019; (10(5)):1801-1809 doi:10.1007/s13300-019-0644-0.

    PMID: 31321746
  18. 18

    The effect of the intercellular adhesion molecule-1 and glycated haemoglobin on the management of diabetic neovascular glaucoma.

    Guzun OV, Zadorozhnyy OS, Velychko LM, et al.

    Romanian journal of ophthalmology 2024; (68(2)):135-142 doi:10.22336/rjo.2024.25.

    PMID: 39006326
  19. 19

    Widefield swept-source optical coherence tomography angiography metrics associated with neovascular glaucoma in patients with proliferative diabetic retinopathy.

    Lu ES, Cui Y, Le R, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2024; (262(4)):1111-1120 doi:10.1007/s00417-023-06290-z.

    PMID: 37962666
  20. 20

    Ischemic index and distribution of retinal capillary non-perfusion in neovascular glaucoma.

    DeBoer C, Wong B, Ameri H

    Frontiers in bioscience (Landmark edition) 2022; (27(1)):24 doi:10.31083/j.fbl2701024.

    PMID: 35090329
  21. 21

    A Comparison of All-Cause Mortality in Patients Who Required Glaucoma Surgery for Neovascular Glaucoma or Primary Open-Angle Glaucoma: A Retrospective Cohort Study.

    Palmer LD, Kauffman LD, Russell GB, et al.

    Vision (Basel, Switzerland) 2025; (9(2)) doi:10.3390/vision9020049.

    PMID: 40559712

This page provides educational information about neovascular glaucoma prognosis and long-term monitoring. Always consult your ophthalmologist or glaucoma specialist for personalized advice regarding your vision and treatment plan.

Get notified when new evidence is published on Neovascular glaucoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.